Results for tag: "Leukodystrophy Drug"

Leukodystrophy is a rare genetic disorder that affects the white matter of the brain, leading to progressive neurological decline. Central nervous system (CNS) drugs are used to treat the symptoms of leukodystrophy, including seizures, cognitive impairment, and motor dysfunction. These drugs are typically administered orally or intravenously, and may include anticonvulsants, antipsychotics, and muscle relaxants. The leukodystrophy drug market is a rapidly growing segment of the CNS drug market, driven by the increasing prevalence of leukodystrophy and the need for effective treatments. The market is expected to benefit from the development of new drugs and the introduction of innovative delivery systems. Some of the major companies in the leukodystrophy drug market include Biogen, Novartis, Sanofi, Pfizer, and Merck. These companies are actively involved in the development of new drugs and delivery systems for leukodystrophy, as well as in the marketing and distribution of existing drugs. Show Less Read more